ESC 23: Hot Line & Late-breaking Science Video Collection

Published: 04 August 2023

  • Views:

    Views Icon 4103

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

What's hot at the European Society of Cardiology (ESC) Congress 2023?

Browse our curated coverage of the latest updates in cardiology from Amsterdam.

  • Watch our View From the Thoraxcenter series for a concise line up of the most awaited trials from Prof Nicolas Van Mieghem and Dr Joost Daemen. 
  • For a deeper dive into key clinical trial data and its applicability, host, Dr Harriette Van Spall meets with Principal Investigators in her Late-Breaker Discussion series.
  • View a condensed summary of the crucial takeaways from each day in our Wrap-Up series with Dr Mirvat Alasnag.
  • Our short, accessible Expert Interviews with select faculty focus on data, patient care and the future of their field.
  • We will feature personal perspective in Behind the Heart series focusing on career pathways, personal motivations and perspectives on the field.

More from this programme

Part 1

View From the Thoraxcenter

2 sessions
ESC 23 Late-breaking Science Wrap Up Watch now
ESC 23 Late-breaking Science Preview Watch now

Part 2

Late-Breaker Discussions with Dr Harriette Van Spall

4 sessions
The ECLS-Shock Trial Watch now
The STEP HFpEF Trial Watch now
The RECORD MI Registry Watch now
Heart Failure at ESC 2023: Recapitulations, Postulations, Predictions Watch now

Part 3

Daily Wrap-Ups with Dr Alasnag & Dr Al-Shaibi

4 sessions
Day 1 Highlights: New Guidelines, STEP-HFpEF, COP-AF Watch now
Day 2 Highlights: BUDAPEST-CRT, FIRE, ECLS-Shock, STOPDAPT-3 Watch now
Day 3 Highlights: OCT Trials, MULTISTARS-AMI, ATTRibute-CM Watch now
Day 4 Highlights: OPT-BIRISK & NITRATE-CIN Watch now

Part 4

Expert Interviews

25 sessions
New Guidelines For the Management of Acute Coronary Syndromes Watch now
NOAH-AFNET 6: Oral Anticoagulation in Pts With AHRE Watch now
LODESTAR: Rosuvastatin Vs Atorvastatin Treatment For CAD Patients Watch now
Economic Burden of Cardiovascular Disease in the EU Watch now
OCEAN(a)-DOSE: Olpasiran in Patients with Atherosclerotic CVD and Elevated LP(a) Watch now
STOPDAPT-3: Prasugrel Monotherapy Without Aspirin in Acute Coronary Syndrome Patients Watch now
HEART-FID: Ferric Carboxymaltose in HF with Iron Deficiency Watch now
SurHyb Trial: Hybrid Ablation in Persistent Atrial Fibrillation Watch now
COMPARE-CRYO: PolarX Vs Arctic Front Cryoballoons for PVI in Pts With Paroxysmal AF Watch now
ILUMIEN IV: OCT Vs Angiography Watch now
ReDS-SAFE HF: ReDS-Guided Strategy in Heart Failure Watch now
MULTISTARS AMI: Immediate Vs Staged PCI in STEMI and MVD Watch now
OCT Vs IVUS Vs Angiography Guidance Watch now
OCTOBER: OCT-Guided or Angiography-Guided PCI in Complex Bifurcation Lesions Watch now
DANPACE II: Reducing Atrial Pacing in Sinus Node Disease Watch now
COP-AF: Colchicine for Perioperative AF Watch now
CASTLE-HTx: Catheter Ablation for AF in Pts with Heart Failure Watch now
OCTIVUS: OCT Vs IVUS-Guided Percutaneous Coronary Intervention Watch now
PUSH-AHF: Natriuresis-Guided Therapy in Acute Heart Failure Watch now
LIBerate-HeFH: Novel PCSK9-Inhibitor in Heterozygous Familial Hypercholesterolemia Watch now
ONCO DVT: Optimal Duration of DOAC Therapy for IDDVT Patients with Cancer Watch now
ATTRibute-CM Trial Watch now
RIGHT: Post-PPCI Anticoagulation in STEMI Patients Watch now
ARAMIS: Anakinra versus Placebo in Acute Myocarditis Watch now
FRAIL-AF: Non-Vitamin K Antagonist Anticoagulation in Frail Elderly Patients With AF Watch now

Part 5

Women as One & Radcliffe Cardiology Presents

2 sessions
Takeaways from ESC 2023 with Dr Cvijic & Dr Grapsa Watch now
Takeaways from ESC 2023 with Dr Al-Lamee, Dr Colleran & Dr Paradies Watch now

Part 6

Behind the Heart

23 sessions
Leadership in Guidelines and Cardiovascular Education with Dr Robert Byrne Watch now
Patient Care and Treatment Strategies with Dr Myeong-Ki Hong Watch now
Challenges and Opportunities in Investigator-Initiated Trials with Dr Paulus Kirchhof Watch now
Intersection of Politics and Medicine with Dr Luengo-Fernandez Watch now
Choosing Cardiology and Advice to Researchers with Dr Robert Mentz Watch now
Leadership in the Context of Clinical Trials with Dr Michelle O'Donoghue Watch now
Trials to Watch Out For with Dr Masahiro Natsuaki Watch now
Introducing Insights from New Data Into Clinical Practice with Dr Alan Bulava Watch now
Emerging Topics in Electrophysiology with Dr Tobias Reichlin Watch now
Key Trials and Data from ESC 23 with Dr Ziad Ali Watch now
Maintaining a Balance of Clinical Skills and New Data with Dr Jesus Alvarez-Garcia Watch now
Inspiring Teams with Prof Barbara Stahli Watch now
Advice for Early-Career Researchers from Dr Gregg Stone Watch now
New Technologies in Electrophysiology with Dr Mads Brix Kronborg Watch now
Considering Unmet Needs in Patient Care with Dr Duk-Woo Park Watch now
Improving Clinical Practice with Dr Do-Yoon Kang Watch now
Contributing to the Guidelines with Dr Jozine Ter Maaten Watch now
Emerging Trends in Amyloidosis with Prof Julian Gillmore Watch now
Working With Role Models with Dr Yan Yan Watch now
The Importance of Mentorship with Dr Giles Montalescot Watch now
Personalised Medicine & Team Approach With Dr Christian Sohns Watch now
Advancement of EP & Adapting New Approaches With Dr Philipp Sommer Watch now
Familial Hypercholesterolemia: Early Detection & Hope for Future Care With Dr Frederick Raal Watch now

About the episode

ESC 2023 — Prof Julian Gillmore (University College London, UK) joins us onsite to discuss the findings of the ATTRibute-CM Study. 

ATTRibute-CM was a randomised double-blind trial which aimed to evaluate the safety and efficacy of acoramidis in a cohort of patients diagnosed with transtherytin amyloid cardiomyopathy (ATTR-CM). 632 patients were enrolled in the trial, and were randomised 2:1 to receive either oral acoramidis 800mg twice daily, or placebo for 30 months. Patients had the option tafmidis after 12 months. 

Results showed that acoramidis improved outcomes in patients with ATTR-CM when compared to placebo, with an absolute risk reduction of 6.4%, relative risk reduction of 25%, and a hazard ratio of 0.772.

Recorded on-site at ESC Congress 2023, Amsterdam.

Editors: Mirjam Boros and Jordan Rance
Video Specialists: Dan Brent, Tom Green, Mike Knight, Oliver Miles

Faculty Biographies

Julian Gillmore

Julian Gillmore

Julian Gillmore gained his medical degree at University of London. He trained in nephrology and undertook MD and PhD degrees in the field of amyloidosis. His research interests include pathogenesis, diagnosis and treatment of amyloidosis.

View full profile

Comments

You must be to comment. If you are not registered, you can register here.